Table 1 Baseline demographic and clinical characteristics
Characteristics | Total n = 155 | Survivors n = 81 (%) | Non survivors n = 74 (%) | p-value |
|---|---|---|---|---|
Age (Mean ± SD) | 36.65 ± 12.93 | 35.96 ± 13.17 | 37.42 ± 12.71 | 0.485 |
Gender: Male | 93 | 46 (56.79) | 47 (63.51) | 0.393 |
Polymyxin E (colistin) resistance(n = 146) | 31 | 14 (21.21) | 17 (21.25) | 0.996 |
Risk factors | ||||
Hematologic condition | ||||
Benign | 35 | 14 (17.28) | 21 (28.38) | 0.307 |
Acute myeloid leukemia | 51 | 31 (38.27) | 20 (27.03) | |
Acute lymphoblastic leukemia | 33 | 17 (20.99) | 16 (21.62) | |
Other malignant conditions | 36 | 19 (23.46) | 17 (22.97) | |
No recovery from neutropenia | 66 | 15 (18.52) | 51 (68.92) | < 0.001 |
Prolonged and profound neutropeniaa | 40 | 24 (29.63) | 16 (21.62) | 0.255 |
Transplant | 55 | 33 (40.74) | 22 (29.73) | 0.152 |
Intensive care requirement | 106 | 38 (46.91) | 68 (91.89) | < 0.001 |
Presence of septic shock | 107 | 37 (45.68) | 70 (94.59) | < 0.001 |
Dialysis requirement | 19 | 3 (3.7) | 16 (21.62) | 0.001 |
Infection details Primary organism Klebsiella pneumoniae | 124 | 66 (81.48) | 58 (78.38) | 0.063 |
Previous bacterial infections | 44 | 22 (27.16) | 22 (29.73) | 0.723 |
Concomitant bacterial infections | 34 | 13 (16.05) | 21 (28.38) | 0.064 |
Cytomegalovirus reactivation b (n = 55) | 6 | 2 (6.06) | 4 (18.18) | 0.158 |
Source of bacteremia: probable gut translocation c | 109 | 58 (71.6) | 51 (68.92) | 0.715 |
Previous exposure to polymyxin | 94 | 46 (56.79) | 48 (64.86) | 0.304 |
Previous exposure to carbapenem | 142 | 74(91.36) | 68 (91.89) | 0.905 |
Persistent bacteremia | 68 | 26 (32.1) | 42 (56.76) | 0.002 |
Duration of persistent bacteremia (n=68; Median (IQR)) | 4 (3–7.5) | 4 (3–7) | 5 (3–8) | 0.265 |
Treatment details | ||||
Polymyxin-based therapy | 75 | 34 (41.98) | 41 (55.41) | 0.299 |
Ceftazidime-avibactam-based | 20 | 10(12.35) | 10(13.51) | |
Therapy | 53 | 33(40.74) | 20(27.03) | |
Polymyxin with ceftazidime-avibactam combination alternate agents | 7 | 4(4.94) | 3(4.05) | |
No appropriate empirical therapy receivedd | 45 | 31(38.27) | 14(18.92) | 0.008 |